News By Tag
News By Place
Follow on Google News
Deciding Patient Factors for HCPs in the Multiple Sclerosis Marketplace
By: Vivisum Partners, LLC
For example, according to Multiple Sclerosis Competitive Landscape, neurologists view Mavenclad's patients as distinct from a treatment in the marketplace like Mayzent, whose more ideal patient has more severe symptoms and have failed 1 previous DMT. A more veteran treatment, such as Kesimpta, has a similar profile to Mayzent-apart from Age, which will be an important factor for marketing to HCPs to assist in narrowing down options available in the multiple sclerosis marketplace.
However, it is Ocrevus, not Mayzent that is seen as a main competitor in the multiple sclerosis marketplace. HCPs view Mayzent as a "Robin Hood,", -reflecting emotions of helpful creativity and non-conformity; "Mayzent is most competitive for patients who have moderate to severe disease, failed 1 DMT, and are younger" said Vivisum's multiple sclerosis strategist Ellen Hart.
Mavenclad differs from Mayzent patients in their disease severity and is viewed as "Nelson Mandela,", reflecting strong and inspirational leadership; Mavenclad's more ideal patient having Mild to Moderate symptoms as opposed to Mayzent's moderate to severe patients.
The market research contained in Multiple Sclerosis Competitive Landscape, found at https://vivisumpartners.com/
Multiple Sclerosis Competitive Landscape Analysis, published in October 2022 by Vivisum Partners, examines each multiple sclerosis drug's strengths and weaknesses across six key clinical attributes:
ABOUT VIVISUM PARTNERS, LLC
Vivisum Partners, LLC is a market research agency providing strategic consulting around marketing and brand building. Vivisum provides facilitated discovery using market research methodologies and critical thinking processes. The actionable market research insights that Vivisum provides enable clients to shape their commercial strategies.
Account Email Address Account Phone Number Disclaimer Report Abuse